vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $13.3M, roughly 1.7× OCULAR THERAPEUTIX, INC). BGSF, INC. runs the higher net margin — -5.3% vs -488.0%, a 482.7% gap on every dollar of revenue. On growth, BGSF, INC. posted the faster year-over-year revenue change (-9.4% vs -22.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-57.1M). Over the past eight quarters, BGSF, INC.'s revenue compounded faster (-5.3% CAGR vs -5.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
BGSF vs OCUL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $13.3M |
| Net Profit | $-1.2M | $-64.7M |
| Gross Margin | 35.0% | 88.0% |
| Operating Margin | -17.6% | -526.5% |
| Net Margin | -5.3% | -488.0% |
| Revenue YoY | -9.4% | -22.4% |
| Net Profit YoY | -18.2% | -33.6% |
| EPS (diluted) | $-0.12 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $13.3M | ||
| Q3 25 | $26.9M | $14.5M | ||
| Q2 25 | $23.5M | $13.5M | ||
| Q1 25 | $20.9M | $10.7M | ||
| Q4 24 | $24.3M | $17.1M | ||
| Q3 24 | $29.8M | $15.4M | ||
| Q2 24 | $25.7M | $16.4M | ||
| Q1 24 | $24.5M | $14.8M |
| Q4 25 | $-1.2M | $-64.7M | ||
| Q3 25 | $-5.8M | $-69.4M | ||
| Q2 25 | $-3.7M | $-67.8M | ||
| Q1 25 | $-722.0K | $-64.1M | ||
| Q4 24 | $-981.0K | $-48.4M | ||
| Q3 24 | $-804.0K | $-36.5M | ||
| Q2 24 | $-761.0K | $-43.8M | ||
| Q1 24 | $-792.0K | $-64.8M |
| Q4 25 | 35.0% | 88.0% | ||
| Q3 25 | 35.9% | 87.8% | ||
| Q2 25 | 35.8% | 85.6% | ||
| Q1 25 | 36.2% | 88.2% | ||
| Q4 24 | 35.9% | 92.8% | ||
| Q3 24 | 35.9% | 89.9% | ||
| Q2 24 | 37.3% | 90.8% | ||
| Q1 24 | 38.1% | 91.0% |
| Q4 25 | -17.6% | -526.5% | ||
| Q3 25 | -3.5% | -472.3% | ||
| Q2 25 | -18.8% | -502.6% | ||
| Q1 25 | 1.6% | -597.5% | ||
| Q4 24 | -15.7% | -296.1% | ||
| Q3 24 | -3.4% | -298.2% | ||
| Q2 24 | -5.7% | -265.1% | ||
| Q1 24 | 1.7% | -214.0% |
| Q4 25 | -5.3% | -488.0% | ||
| Q3 25 | -21.6% | -477.3% | ||
| Q2 25 | -15.9% | -503.9% | ||
| Q1 25 | -3.5% | -598.7% | ||
| Q4 24 | -4.0% | -283.3% | ||
| Q3 24 | -2.7% | -236.6% | ||
| Q2 24 | -3.0% | -266.3% | ||
| Q1 24 | -3.2% | -438.9% |
| Q4 25 | $-0.12 | $-0.27 | ||
| Q3 25 | $-0.52 | $-0.38 | ||
| Q2 25 | $-0.34 | $-0.39 | ||
| Q1 25 | $-0.06 | $-0.38 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | $-0.07 | $-0.22 | ||
| Q2 24 | $-0.07 | $-0.26 | ||
| Q1 24 | — | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $737.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $654.3M |
| Total Assets | $57.8M | $808.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $737.1M | ||
| Q3 25 | $41.2M | $344.8M | ||
| Q2 25 | $2.8M | $391.1M | ||
| Q1 25 | $2.0M | $349.7M | ||
| Q4 24 | $32.0K | $392.1M | ||
| Q3 24 | $262 | $427.2M | ||
| Q2 24 | $226 | $459.7M | ||
| Q1 24 | $50 | $482.9M |
| Q4 25 | $48.1M | $654.3M | ||
| Q3 25 | $50.7M | $258.2M | ||
| Q2 25 | $78.3M | $305.9M | ||
| Q1 25 | $81.8M | $265.9M | ||
| Q4 24 | $82.3M | $315.3M | ||
| Q3 24 | $82.9M | $352.0M | ||
| Q2 24 | $83.2M | $377.7M | ||
| Q1 24 | $83.6M | $408.0M |
| Q4 25 | $57.8M | $808.1M | ||
| Q3 25 | $83.6M | $410.9M | ||
| Q2 25 | $149.7M | $451.3M | ||
| Q1 25 | $152.3M | $405.9M | ||
| Q4 24 | $150.1M | $457.9M | ||
| Q3 24 | $157.3K | $490.4M | ||
| Q2 24 | $159.8K | $517.1M | ||
| Q1 24 | $170.6K | $538.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-54.2M |
| Free Cash FlowOCF − Capex | $1.7M | $-57.1M |
| FCF MarginFCF / Revenue | 7.6% | -430.9% |
| Capex IntensityCapex / Revenue | 0.1% | 21.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-54.2M | ||
| Q3 25 | $-4.8M | $-50.7M | ||
| Q2 25 | $2.2M | $-55.2M | ||
| Q1 25 | $1.1M | $-44.7M | ||
| Q4 24 | $3.2M | $-39.4M | ||
| Q3 24 | $6.5M | $-36.6M | ||
| Q2 24 | $7.3M | $-24.8M | ||
| Q1 24 | $7.4M | $-33.9M |
| Q4 25 | $1.7M | $-57.1M | ||
| Q3 25 | $-4.9M | $-56.7M | ||
| Q2 25 | $2.1M | $-56.5M | ||
| Q1 25 | $1.0M | $-46.6M | ||
| Q4 24 | $2.5M | $-39.6M | ||
| Q3 24 | $6.5M | $-36.6M | ||
| Q2 24 | $7.3M | $-25.5M | ||
| Q1 24 | $6.9M | $-34.1M |
| Q4 25 | 7.6% | -430.9% | ||
| Q3 25 | -18.1% | -390.0% | ||
| Q2 25 | 9.1% | -419.7% | ||
| Q1 25 | 5.0% | -435.6% | ||
| Q4 24 | 10.2% | -232.0% | ||
| Q3 24 | 21.7% | -237.6% | ||
| Q2 24 | 28.5% | -155.4% | ||
| Q1 24 | 28.1% | -231.1% |
| Q4 25 | 0.1% | 21.4% | ||
| Q3 25 | 0.4% | 41.2% | ||
| Q2 25 | 0.0% | 9.3% | ||
| Q1 25 | 0.1% | 18.1% | ||
| Q4 24 | 3.0% | 1.2% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 4.5% | ||
| Q1 24 | 2.0% | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
OCUL
Segment breakdown not available.
